Treatment Updates in Chronic Lymphocytic Leukemia

home / insights / cll-treatment-updates
TP53 and Deletion 17p as Prognostic Factors in CLL

EP. 1: TP53 and Deletion 17p as Prognostic Factors in CLL

March 31st 2018
Other Prognostic Factors in Chronic Lymphocytic Leukemia

EP. 2: Other Prognostic Factors in Chronic Lymphocytic Leukemia

March 31st 2018
Impact of Prognostic Factors on Clinical Decisions in CLL

EP. 3: Impact of Prognostic Factors on Clinical Decisions in CLL

March 31st 2018
Evolution of Biological Understandings in CLL

EP. 4: Evolution of Biological Understandings in CLL

March 31st 2018
Selecting the Optimal Frontline Therapy in CLL

EP. 5: Selecting the Optimal Frontline Therapy in CLL

March 31st 2018
Sequencing Strategies in Frontline CLL

EP. 6: Sequencing Strategies in Frontline CLL

March 31st 2018
Ibrutinib's Value as Frontline Therapy in CLL

EP. 7: Ibrutinib's Value as Frontline Therapy in CLL

March 31st 2018
Novel Frontline Combinations With Ibrutinib in CLL

EP. 8: Novel Frontline Combinations With Ibrutinib in CLL

March 31st 2018
Approaching Therapy for Relapsed/Refractory CLL

EP. 9: Approaching Therapy for Relapsed/Refractory CLL

March 31st 2018
CLL: Post-Ibrutinib or Chemoimmunotherapy Approaches

EP. 10: CLL: Post-Ibrutinib or Chemoimmunotherapy Approaches

March 31st 2018
Evaluating Pharmacologic Agents in Relapsed/Refractory CLL

EP. 11: Evaluating Pharmacologic Agents in Relapsed/Refractory CLL

March 31st 2018
Continuing Therapy in Relapsed/Refractory CLL

EP. 12: Continuing Therapy in Relapsed/Refractory CLL

March 31st 2018
Novel Approaches to Treating Relapsed/Refractory CLL

EP. 13: Novel Approaches to Treating Relapsed/Refractory CLL

March 31st 2018
Relapsed/Refractory CLL: Evaluating Other Novel Agents

EP. 14: Relapsed/Refractory CLL: Evaluating Other Novel Agents

March 31st 2018
The Evolving Treatment Landscape of CLL

EP. 15: The Evolving Treatment Landscape of CLL

March 31st 2018